Impact of an ultrasensitive Cytomegalovirus quantitative nucleic acid test on Cytomegalovirus detection and therapy in renal transplant recipients.
Vivek Bhika BeecharStephanie Marie PouchVarun K PhadkeGeeta KaradkheleChristian P LarsenMichael H WoodworthPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2023)
The use of ultrasensitive CMV qNAT assays in moderate-risk CMV renal transplant recipients is associated with earlier detection and longer durations of CMV DNAemia without impacting CMV end-organ disease or 1-year mortality.